Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-414 in Japanese Subjects With Malignant Glioma
NCT02590263Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2015
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of depatuxizumab mafodotin in malignant glioma, glioblastoma multiforme (GBM), sponsored by AbbVie Inc.. Started Aug 2015; status: completed.
02
Drugs
depatuxizumab mafodotin
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02590263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590263.